Chenglei Gu

512 total citations
29 papers, 368 citations indexed

About

Chenglei Gu is a scholar working on Molecular Biology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Chenglei Gu has authored 29 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Reproductive Medicine and 8 papers in Obstetrics and Gynecology. Recurrent topics in Chenglei Gu's work include Endometriosis Research and Treatment (8 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Cancer-related molecular mechanisms research (5 papers). Chenglei Gu is often cited by papers focused on Endometriosis Research and Treatment (8 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Cancer-related molecular mechanisms research (5 papers). Chenglei Gu collaborates with scholars based in China, United States and United Kingdom. Chenglei Gu's co-authors include Wensheng Fan, Mingxia Ye, Luyang Zhao, Zhe Zhang, Yuanguang Meng, Yuanguang Meng, Lian Li, Weidong Han, Mingxia Li and Min Wang and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and European Journal of Medicinal Chemistry.

In The Last Decade

Chenglei Gu

25 papers receiving 364 citations

Peers

Chenglei Gu
Katharina Proestling Austria
Zongfeng Zhang China
Chengcheng Ning China
Yuanxi Zhu China
Linjuan Xu China
J Belotte United States
Salah T. Fayed Egypt
Mingbo Cai China
Lina Albitar United States
Yuko Shiroyama Japan
Katharina Proestling Austria
Chenglei Gu
Citations per year, relative to Chenglei Gu Chenglei Gu (= 1×) peers Katharina Proestling

Countries citing papers authored by Chenglei Gu

Since Specialization
Citations

This map shows the geographic impact of Chenglei Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenglei Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenglei Gu more than expected).

Fields of papers citing papers by Chenglei Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenglei Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenglei Gu. The network helps show where Chenglei Gu may publish in the future.

Co-authorship network of co-authors of Chenglei Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Chenglei Gu. A scholar is included among the top collaborators of Chenglei Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenglei Gu. Chenglei Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Tong, Chenglei Gu, Qi Chen, et al.. (2025). Novel agents derived from natural product β-elemene: A second round of design and synthesis to enhance antitumor properties. Bioorganic & Medicinal Chemistry. 121. 118129–118129.
2.
3.
Li, Shijia, Ziwei Tang, Yanyan Feng, et al.. (2025). Tubulin-based dual-target compounds and protein degraders for cancer therapy—An updated review (2021-present). European Journal of Medicinal Chemistry. 301. 118191–118191.
4.
Tang, Ziwei, Cheng Chen, Tong Li, et al.. (2025). Insights into tumor-derived exosome inhibition in cancer therapy. European Journal of Medicinal Chemistry. 285. 117278–117278. 6 indexed citations
5.
Gu, Chenglei, Chen Zhou, Chunqin Mao, et al.. (2024). Insights into direct KRAS inhibition strategies for cancer treatment. Future Medicinal Chemistry. 16(22). 2411–2429. 1 indexed citations
6.
7.
8.
Chen, Cheng, Ziwei Tang, Zhang Ye, et al.. (2024). Development of natural product-based targeted protein degraders as anticancer agents. Bioorganic Chemistry. 153. 107772–107772. 5 indexed citations
9.
Gu, Chenglei, Luyang Zhao, Feng Liu, et al.. (2024). Identification of 10 differentially expressed genes involved in the tumorigenesis of cervical cancer via next-generation sequencing. PeerJ. 12. e18157–e18157. 1 indexed citations
10.
11.
Chen, Jichao, Kan Yang, Jiahe Wang, et al.. (2023). Design, synthesis and biological evaluation of novel 9-N-substituted-13-alkylberberine derivatives from Chinese medicine as anti-hepatocellular carcinoma agents. Bioorganic & Medicinal Chemistry. 79. 117156–117156. 5 indexed citations
12.
Gu, Chenglei, Yuanguang Meng, Wensheng Fan, et al.. (2021). Exploring the Potential Key IncRNAs with Endometriosis by Construction of a ceRNA Network. International Journal of General Medicine. Volume 14. 4161–4170. 13 indexed citations
13.
Gu, Chenglei, Zhe Zhang, Wensheng Fan, et al.. (2020). Identification of MicroRNAs as Potential Biomarkers in Ovarian Endometriosis. Reproductive Sciences. 27(9). 1715–1723. 21 indexed citations
14.
Ye, Mingxia, Qian Zhang, Zhen Li, Chenglei Gu, & Yuanguang Meng. (2020). Robotic CSP Resection and Hysterotomy Repair. Journal of Minimally Invasive Gynecology. 28(5). 945–946. 5 indexed citations
15.
Zhang, Huijuan, et al.. (2019). <p>Sanguinarine exhibits potent efficacy against cervical cancer cells through inhibiting the STAT3 pathway in vitro and in vivo</p>. Cancer Management and Research. Volume 11. 7557–7566. 19 indexed citations
16.
Ye, Mingxia, Min Wang, Mingxia Li, et al.. (2018). Effect of Mst1 on Endometriosis Apoptosis and Migration: Role of Drp1-Related Mitochondrial Fission and Parkin-Required Mitophagy. Cellular Physiology and Biochemistry. 45(3). 1172–1190. 42 indexed citations
17.
Zhao, Luyang, Chenglei Gu, Mingxia Ye, et al.. (2018). Integration analysis of microRNA and mRNA paired expression profiling identifies deregulated microRNA-transcription factor-gene regulatory networks in ovarian endometriosis. Reproductive Biology and Endocrinology. 16(1). 4–4. 64 indexed citations
18.
Wang, Min, Wensheng Fan, Mingxia Ye, et al.. (2018). Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. Scientific Reports. 8(1). 8990–8990. 35 indexed citations
19.
Zhao, Luyang, Chenglei Gu, Ke Huang, et al.. (2016). Association between oestrogen receptor alpha (ESR1) gene polymorphisms and endometriosis: a meta-analysis of 24 case-control studies. Reproductive BioMedicine Online. 33(3). 335–349. 19 indexed citations
20.
Zhao, Luyang, Chenglei Gu, Ke Huang, et al.. (2016). Endometriosis research using capture microdissection techniques: Progress and future applications. Biomedical Reports. 5(5). 531–540. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katharina Proestling Breakdown of academic impact, for papers by Zongfeng Zhang Breakdown of academic impact, for papers by Chengcheng Ning Breakdown of academic impact, for papers by Yuanxi Zhu Breakdown of academic impact, for papers by Linjuan Xu Breakdown of academic impact, for papers by J Belotte Breakdown of academic impact, for papers by Salah T. Fayed Breakdown of academic impact, for papers by Mingbo Cai Breakdown of academic impact, for papers by Lina Albitar Breakdown of academic impact, for papers by Yuko Shiroyama
Rankless by CCL
2026